Navigation Links
Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting

sentations at DDW

Favorable Cross-Resistance Profile of HCV-796 and Boceprevir (SCH-503034) and Enhanced Anti-Replicon Activity Mediated By Combination Treatment; R. Ralston, Monday, May 21, 11:15 a.m., Room 206

Pharmacodynamic Analysis of the Antiviral Activity of the Non-Nucleoside Polymerase Inhibitor, HCV-796, in Combination With Peginterferon Alfa-2b in Treatment-Naive Patients With Chronic HCV; E.S. Maller, Monday, May 21, 2:15 p.m., Room 206

Phase II Study of celgosivir in combination with Peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 nonresponder patients; K.D. Kaita, Monday, May 21, 2:45 p.m., Room 206

    Schering-Plough Sponsored CME Symposium


    "HCV Treatment Decisions: Challenging Issues"

    Monday, May 21, 6:30-8:30 pm, Grand Hyatt Washington,

    Independence Ballroom A, 1000 H Street, NW, Washington, D.C.

This case-based symposium is designed to outline effective management strategies for patients with hepatitis C virus infection. Optimizing HCV patient outcome requires a thorough understanding of the underlying patient and disease factors that influence treatment. Clinical scenarios will be presented, and through the use of case studies, the distinguished faculty will review and discuss current data to illustrate their respective treatment decisions.

About PEGINTRON and REBETOL Combination Therapy

PEGINTRON is approved in the United States for use alone or with ribavirin (800 mg/day) for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age.

WARNING

Alpha interferons, including PEGINTRON, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsen
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
2. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:10/8/2008)...atments for Spinal Cord, Other Nerve,Injuries -, ...protein that enables,nerve cells to communicate wi...developing nervous system. Research into how that ...rve cells may provide a basis for eventual,treatme...ous system,including spinal cord injury., "This ...
(Date:10/8/2008)...continued and Headcount to be Reduced, Summary: Ge...; Zanolimumab Program to be Discontinued and the ... Employees, COPENHAGEN, October 8 /P...unced today that it is discontinuing development o...sult of a portfolio review and,assessment of the o...
(Date:10/8/2008)...TAXUS(R) Element(TM) Platinum Chromium ... /- Boston Scientific,Corpo...ompleted enrollment in,the PERSEUS trial, designed...R) Element(TM) paclitaxel-eluting coronary stent. ...,500 patients at 100 U.S. and,international center...
(Date:10/8/2008)... -- Vical Incorporated (Nasdaq: VICL ),today is p...al data,demonstrating that the company,s Vaxfectin... protein-based infectious disease vaccines and,pep...m.D., Ph.D., Vical,s,Senior Vice President of Prod...esday, October 8, at the World Vaccine Congress (L...
Breaking Medicine Technology:Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Saving Lives of Florida Residents Who Develop Skin Cancer Each Year 3A The Key is Early Detection and Treatment 252 1Saving Lives of Florida Residents Who Develop Skin Cancer Each Year 3A The Key is Early Detection and Treatment 252 2CABI helps phase out dangerous pesticide in EU 356 1CABI helps phase out dangerous pesticide in EU 356 2Microbiotic technology developed for microinjection of zebrafish embryos 1069 1Family Dinners Shape Healthier Eating Habits 1065 1
...--May 15, 2007 - Synthetic Blood,International, In...,a statistical analysis of its Phase IIa study wit...ury. In line with preliminary,study results announ...d that the primary endpoint of increasing patients... met. Data also show a,decrease in patient glucose...
... 17, 2007 - Salix,Pharmaceuticals, Ltd. (NASDAQ:SL...r-initiated trials related to the Company,s produc...2007, which will be,held May 19-24, 2007. Digestiv...prestigious meeting in the world for the GI,profes...ysicians,researchers and academics from around th...
Other Medicine Technology:Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5
(Date:10/10/2008)...10 /PRNewswire-FirstCall/ -- Hologic, Inc.,(Nasdaq...upplier of premium,diagnostics, medical imaging sy...he healthcare needs of women, today announced plan...erating results on Tuesday, November 11,2008 afte...anagement will,host a conference call on Tuesday, ...
(Date:10/10/2008)... Upon the completion of a highly successful CIO Fi...roudly announces their next business technology ga...ology executives in healthcare. CDM Media has conf...-12, 2009 at the Four Seasons Resort in Scottsdale...EB) October 11, 2008 -- Upon the completion of a h...
(Date:10/10/2008)... 10 /PRNewswire/ -- NuView Life Sciences Inc.,(NuV... Sciences Inc.,(Trace), including operations of th...lities in Denton, Texas. The Trace facility produc...nd Thallium-201 used in,molecular imaging and nucl... stated that "We are confident that by improving o...
(Date:10/10/2008)...Calif., Oct. 10 /PRNewswire/ -- A senior citizen,s...ountains in a small,plane. The high-flying adventu.... The thrill came from a last-wish program through...nior Living, where Heden was a patient.,Called Go ...it has helped,many realize a special activity at t...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:CIO Healthcare Summit Announces Dates and VIP Delegates 2Health News:Deck of Cards is More Than a Game: Integral in Silverado Hospice Care 2
...ork-Presbyterian Hospital/Weill Cornell Medical Ce...nts the ability of an antibody to directly target ...ing healthy tissues unharmed. The Phase I clinica..., targeted to the prostate specific membrane antig...
...y 40% of the doctors in one Russian city have late...ho work in TB clinics. The research has been publi...oblem worldwide. Russia is one country where it is... third of the world's population are infected with...
... standard breast cancer therapy drug tamoxifen, to...s by almost one-fifths. Publishing their finding... Dr. Francesco Boccardo of the National Cancer Res... changing treatments tracks to exemestane after 2 ...
...r from persistent iron overload has been cleared. ...um. Patients suffering from a rare genetic condit...se need regular blood transfusions. Generally thes... at nights by needle and pump which lasts for arou...
Other Medicine News:Health News:First Treatment to Directly Target Tumor Blood Supply 2Health News:First Treatment to Directly Target Tumor Blood Supply 3Health News:New Drug Therapy for Breast Cancer Offers Hope 2
...dy (IgG) Test is a semiquantitative enzyme immunoa...cant IgG antibodies to M. pneumoniae between acute...should not be used for specimens found reactive wi... Test and is not intended for qualitative (one spe...
...unoassay (EIA) that detects IgG antibodies to Epst...arr early nuclear antigen (EBV-EBNA), cytomegalovi...n with Mono-M Test it is an aid in the serodiagnos...ve serodiagnosis of CMV or Toxoplasma mononucleosi...
The ImmunoDOT TORCH Test is an enzyme immunoassay (EIA) procedure intended for determining the presence of antibodies to Toxoplasma gondii, rubella virus, cytomegalovirus and herpes simplex virus in
...e enzyme immunoassays (EIA) for the presumptive de... IgM, respectively) in serum. Equivocal or positiv...with a standardized western blot procedure. These ...ical diagnosis of B. burgdorferi infection (Lyme d...
Medicine Products: